Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2010 3
2011 3
2012 2
2013 1
2014 1
2015 4
2016 1
2017 5
2018 4
2019 5
2020 4
2021 8
2022 6
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Mastocytosis and Mast Cell Activation Disorders: Clearing the Air.
Jackson CW, Pratt CM, Rupprecht CP, Pattanaik D, Krishnaswamy G. Jackson CW, et al. Among authors: pattanaik d. Int J Mol Sci. 2021 Oct 19;22(20):11270. doi: 10.3390/ijms222011270. Int J Mol Sci. 2021. PMID: 34681933 Free PMC article. Review.
Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus.
Werth VP, Furie RA, Romero-Diaz J, Navarra S, Kalunian K, van Vollenhoven RF, Nyberg F, Kaffenberger BH, Sheikh SZ, Radunovic G, Huang X, Clark G, Carroll H, Naik H, Gaudreault F, Meyers A, Barbey C, Musselli C, Franchimont N; LILAC Trial Investigators. Werth VP, et al. N Engl J Med. 2022 Jul 28;387(4):321-331. doi: 10.1056/NEJMoa2118024. N Engl J Med. 2022. PMID: 35939578 Clinical Trial.
Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus.
Furie RA, van Vollenhoven RF, Kalunian K, Navarra S, Romero-Diaz J, Werth VP, Huang X, Clark G, Carroll H, Meyers A, Musselli C, Barbey C, Franchimont N; LILAC Trial Investigators. Furie RA, et al. N Engl J Med. 2022 Sep 8;387(10):894-904. doi: 10.1056/NEJMoa2118025. N Engl J Med. 2022. PMID: 36069871 Clinical Trial.
Pediatric Angioedema.
Pattanaik D, Lieberman JA. Pattanaik D, et al. Curr Allergy Asthma Rep. 2017 Aug 8;17(9):60. doi: 10.1007/s11882-017-0729-7. Curr Allergy Asthma Rep. 2017. PMID: 28791569 Review.
Endothelial Dysfunction in Systemic Sclerosis.
Patnaik E, Lyons M, Tran K, Pattanaik D. Patnaik E, et al. Among authors: pattanaik d. Int J Mol Sci. 2023 Sep 21;24(18):14385. doi: 10.3390/ijms241814385. Int J Mol Sci. 2023. PMID: 37762689 Free PMC article. Review.
Nonallergic rhinitis.
Lieberman P, Pattanaik D. Lieberman P, et al. Among authors: pattanaik d. Curr Allergy Asthma Rep. 2014 Jun;14(6):439. doi: 10.1007/s11882-014-0439-3. Curr Allergy Asthma Rep. 2014. PMID: 24715611 Review.
Vasomotor rhinitis.
Pattanaik D, Lieberman P. Pattanaik D, et al. Curr Allergy Asthma Rep. 2010 Mar;10(2):84-91. doi: 10.1007/s11882-010-0089-z. Curr Allergy Asthma Rep. 2010. PMID: 20425499 Review.
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, Adams DH, Kerr L, Lee C, Shuler CL, Genovese M; SPIRIT-P2 Study Group. Nash P, et al. Lancet. 2017 Jun 10;389(10086):2317-2327. doi: 10.1016/S0140-6736(17)31429-0. Epub 2017 May 24. Lancet. 2017. PMID: 28551073 Clinical Trial.
46 results